详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Tumor exosome-based drug delivery system targeting ferroptosis and apoptosis for glioblastoma therapy

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]School of Pharmacy, Yantai University, Yantai, China [2]Department of Neurosurgery, The First People’s Hospital of Qinzhou/The tenth Hospital of Guangxi MedicalUniversity, Qinzhou, Guangxi, China [3]Department of Neurosurgery, Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China [4]Department of Neurosurgery, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China [5]Department of Pharmacology, Guang’anmen Hospital of China Academy of Chinese Medical Sciences, Xicheng District, Beijing, China [6]Shandong Institute of Brain Science and Brain-inspired Research, Shandong First Medical University, Jinan, China

出处：

DOI：

ISSN：

关键词： Exosome membrane Glioblastoma Ferroptosis Apoptosis Combination therapy

摘要：

Temozolomide (TMZ) is a first-line chemotherapy drug to treat glioblastoma (GBM), but still encounters blood-brain barrier (BBB), and chemotherapy resistance. To address these issues, sensible combination therapy of TMZ with other novel therapeutic techniques is required. Herein, we developed a tumor cell exosome membrane (EM) based drug delivery platform (EMNPs@TMZ) for encapsulating reactive oxygen species (ROS) responsive fucoidan (Fuc) nanoparticles (FNPs). EMNPs@TMZ system can co-deliver TMZ and luteolin (Lut) for the combined targeting apoptosis and ferroptosis. Interestingly, Lut can induce ferroptosis by inhibiting Nrf2 expression, and also inhibit DNA repair through Wnt/β-catenin, promoting TMZ induced cell apoptosis. More importantly, this nanoparticle drug delivery system has tumor dual-targeting effect, which enhances the inhibitory effect on glioma growth, thereby improving the survival rate of mice models, and has no significant side effects during the treatment process, particularly in the orthotopic patient-derived xenograft (PDX) model. This biomimetic nanoparticle provides a promising strategy for ferroptosis combination chemotherapy for GBM therapy.Copyright © 2025 Elsevier B.V. All rights reserved.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

大类 | 2 区医学

小类 | 1 区生物物理 3 区材料科学：生物材料

最新[2025]版：

大类 | 2 区医学

小类 | 1 区生物物理 3 区材料科学：生物材料

第一作者：

第一作者机构： [1]School of Pharmacy, Yantai University, Yantai, China [3]Department of Neurosurgery, Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

共同第一作者：

通讯作者：

通讯机构： [3]Department of Neurosurgery, Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China [6]Shandong Institute of Brain Science and Brain-inspired Research, Shandong First Medical University, Jinan, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Tumor exosome-based drug delivery system targeting ferroptosis and apoptosis for glioblastoma therapy

文献详情

相关文献